JnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in children Ruchika Sharma3 Dec 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ MedTech gets IDE approval for OTTAVA Robotic Surgical System Ruchika Sharma15 Nov 2024 5:05 PM ISTNew Brunswick: Johnson & Johnson MedTech has announced that the U.S. Food & Drug Administration (USFDA) has approved the OTTAVA...
USFDA grants Breakthrough Therapy Designation to Nipocalimab for treatment of adults with moderate-to-severe Sjögren's disease: JnJ Ruchika Sharma12 Nov 2024 1:00 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy...
JnJ seeks approval from USFDA, EMA for DARZALEX FASPRO as subcutaneous monotherapy for high-risk smoldering multiple myeloma Ruchika Sharma10 Nov 2024 4:15 PM ISTRaritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and...
Shockwave Medical concludes enrollment in all-female coronary IVL study Ruchika Sharma2 Nov 2024 2:16 PM ISTSanta Clara: Shockwave Medical, Inc., part of Johnson & Johnson MedTech has announced the completion of enrollment in EMPOWER CAD, the first...
JnJ completes acquisition of V Wave Ruchika Sharma10 Oct 2024 12:34 PM ISTNew Brunswick: Johnson & Johnson has announced that it has successfully completed the acquisition of V-Wave Ltd., a privately-held company...
JnJ to discontinue Phase 2 Field Study evaluating investigational antiviral for Dengue prevention Ruchika Sharma8 Oct 2024 4:50 PM ISTRaritan: Johnson & Johnson has announced it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational...
JnJ seeks USFDA nod for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned Ruchika Sharma6 Oct 2024 10:30 AM ISTRaritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
NCDRC orders JnJ to pay Rs 35 lakh compensation for faulty hip replacement device Yakshi Chugh3 Oct 2024 6:07 PM ISTIn a significant ruling, the National Consumer Disputes Redressal Commission (NCDRC) has ordered Johnson & Johnson Limited to compensate a...
Apex Consumer Court slaps Rs 35 lakh compensation on Johnson & Johnson for faulty hip replacement device Ruchika Sharma1 Oct 2024 12:35 PM ISTNew Delhi: In a significant ruling, the National Consumer Disputes Redressal Commission (NCDRC) has ordered Johnson & Johnson Limited to...
Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma Ruchika Sharma22 Sept 2024 12:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use...
